Webb et al. Novel CAD Risk Loci and Pleiotropy on the array for identity by descent testing. The results of an analysis of rare (minor-allele frequency <5%) coding sequence ("exome") variants on this array with CAD were recently reported (5).
We identified 6 new loci associated at genome-wide significance with CAD, annotated these, and undertook a detailed examination of the extent of pleiotropy of these loci as well the previously known CAD loci.
METHODS
The study consisted of discovery and replication phases and has been described in more detail elsewhere (5). Briefly, the discovery cohort included 42,335 cases and 78,240 control subjects from 20 individual studies (Online Table 1 control subjects from 8 studies (Online Table 2 ). With the exception of participants from 2 studies in the replication cohort who were of South Asian ancestry, all participants were of European ancestry (Online Table 2 ).
Samples were genotyped on the Illumina (16) .
RESULTS
In the discovery cohort, 28 variants not located in a known CAD locus (defined as AE300 kb from the published lead SNP) showed association with CAD at a p value <1 Â 10 À6 (Online Table 3 ). No marked heterogeneity was observed, justifying the use of a fixedeffects model. We then tested these 28 variants for replication, and 6 variants showed both a nominally significant (p < 0.05) association in the replication cohort and a combined discovery and replication meta-analyses p value exceeding the threshold for genome-wide significance (p < 5 Â 10 À8 ) ( Table 1) . As typical for GWAS findings, the risk alleles were common (allele frequencies ranging from 15% to 86%), and the risk increase per allele was modest (ranging from 4% to 9%) ( Table 1) . Table 4 ). Apart from the lead variant at the KCNJ13-GIGYF2 locus, which is a nonsynonymous SNP, none of the other loci had a variant affecting protein sequence in high LD with the lead variant. Webb et al.
Novel CAD Risk Loci and Pleiotropy ester transfer protein (CETP) gene, which mediates the transfer of cholesteryl esters from HDL cholesterol to other lipoproteins and was placed on the array because of its association with plasma HDL cholesterol level (9, 10) . The risk (C) allele is associated with lower HDL cholesterol and modest increases in plasma LDL cholesterol and triglycerides levels (9, 10) . Previous studies have shown that rs1800775 is itself functional in that the C allele disrupts binding of the Sp1 transcription factor resulting in increased promoter activity (18) . This is in agreement with our annotation, which predicts this to be more likely to be a functional SNP than the only other SNP in high LD, rs3816117 (Online Figure 3) . Consistent with this, we also found associations between rs1800775 and CETP expression (r 2 of 0.77) with the best eSNP (i.e., the lead SNP for the eQTL) in monocytes and liver (Online Table 5 ), and previous studies have shown that the variant is also associated with plasma CETP level (19, 20) . Table 6 ), but a stronger association with plasma LDL cholesterol and triglycerides levels ( Table 2) . rs11957830 was included on the array because of an association of the A allele (CAD risk-associated allele) with higher levels of vitamin E ( Table 3 Table 4 ). The risk (C) allele of the lead variant has previously been associated with reduced risk of migraine (23) , and there is an association of the alternate (T) allele with reduced lung function (24) .
There are also associations at this locus for abdominal aortic aneurysm (25) and triglyceride levels (10); Webb et al.
Novel CAD Risk Loci and Pleiotropy Table 5 ). (cytochrome P450, family 21, subfamily A, polypeptide 2) expression in whole blood (Online Table 5 ).
rs3869109, another variant at the HLA locus approximately 700 kb away from the new lead variant, has been reported to be associated with CAD (27) . In our discovery cohort, rs3869109 has a p value of association with CAD of 0.23. extended linkage at this locus, with more than 100 SNPs in high LD and the lead variant in a region of w170 kb also spanning GIGYF2 (GRB10 interacting GYF protein 2) (Online Figure 3) . KCJN13 is located entirely within GIGYF2 and transcribed in the opposite direction. A number of the associated variants are in annotated regulatory regions, with the top scoring candidate by in silico prediction, rs11555646, lying in the 5 0 -UTR of GIGYF2 close to the initiating methionine (Online Figure 3) . There was no association of the locus with any of the cardiovascular risk factors, but we found eQTLs for the lead variant or a variant in high LD for both GIGFY2 and KCNJ13
(Online Table 5 ). This chord diagram depicts associations that passed Bonferroni correction ( Table 2) . Connections indicate that single nucleotide polymorphisms at respective loci associate with both coronary artery disease (CAD) and the respective risk factor; they do not imply that the risk factor causally explains the association with CAD. Red indicates new CAD loci. BMI ¼ body mass index; HDL ¼ high-density lipoprotein; LDL ¼ low-density lipoprotein.
CENTRAL ILLUSTRATION Significant Associations of CAD Loci With Cardiovascular Risk Factors
Webb et al.
CAD LOCI AND PLEIOTROPY. We undertook an updated analysis of the association of all 62 CAD loci (56 published and 6 novel in this report) with traditional cardiovascular risk factors (blood pressure traits, lipid traits, BMI, type 2 diabetes, and smoking).
The full results are shown in Online Table 6 , and the significant associations are summarized in Table 2 Several loci showed multiple associations ( Table 3) .
Although in most cases, the CAD-associated risk allele was also associated with an increased risk (or level) of the other disease or trait, this was not always the case. Furthermore, in some loci with multiple associations, the direction of association varied between diseases ( Table 3) . Interestingly, despite having higher plasma HDL, 346L carriers had an increased risk of CAD, suggesting that the association of variation at this locus on CAD is not driven primarily through plasma HDL (35) .
Indeed, there is only a nominal association of the lead CAD variant at this locus (rs11057830) with plasma HDL cholesterol (Online Table 6 ). The variant is also modestly associated with plasma LDL cholesterol and serum triglycerides ( Table 2 ). All 3 of these lipid associations are directionally consistent with epidemiological evidence linking them to CAD risk and could, in combination, explain the association of the locus with CAD. However, the lead variant is more strongly associated with Lp-PLA 2 activity and mass (Table 3) 
